July 15, 2025
2 min watch
LOS ANGELES — Xdemvy yielded symptom enhancements in sufferers with Demodex blepharitis, in response to Kendall E. Donaldson, MD, MS.
On the American Society of Cataract and Refractive Surgical procedure assembly, Donaldson introduced knowledge from Orion, a real-world, multicenter examine that seemed on the burden of Demodex blepharitis in 300 sufferers. Sufferers handled with Xdemvy (lotilaner ophthalmic answer 0.25%, Tarsus Prescribed drugs) “improved considerably of their signs” at 6 months whereas visible analog scale scores decreased. Signs elevated in sufferers who weren’t handled with lotilaner.
“We’re persevering with to gather knowledge on these sufferers, however we’re very optimistic that now we’ve got a great therapy for Demodex blepharitis with lotilaner,” Donaldson mentioned.
Sources/Disclosures
Collapse
Donaldson KE, et al. Longitudinal analysis of illness burden and therapy efficacy in sufferers with Demodex blepharitis: Orion registry interim outcomes. Introduced at: American Society of Cataract and Refractive Surgical procedure assembly; April 25-28, 2025; Los Angeles.
Disclosures:
Donaldson reviews consulting for Tarsus Prescribed drugs.
